JP2023500480A5 - - Google Patents

Info

Publication number
JP2023500480A5
JP2023500480A5 JP2022525094A JP2022525094A JP2023500480A5 JP 2023500480 A5 JP2023500480 A5 JP 2023500480A5 JP 2022525094 A JP2022525094 A JP 2022525094A JP 2022525094 A JP2022525094 A JP 2022525094A JP 2023500480 A5 JP2023500480 A5 JP 2023500480A5
Authority
JP
Japan
Application number
JP2022525094A
Other languages
Japanese (ja)
Other versions
JP2023500480A (ja
JPWO2021087016A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/057817 external-priority patent/WO2021087016A1/en
Publication of JP2023500480A publication Critical patent/JP2023500480A/ja
Publication of JP2023500480A5 publication Critical patent/JP2023500480A5/ja
Publication of JPWO2021087016A5 publication Critical patent/JPWO2021087016A5/ja
Priority to JP2025131369A priority Critical patent/JP2025170788A/ja
Pending legal-status Critical Current

Links

JP2022525094A 2019-11-01 2020-10-29 癌の治療のための抗cd27抗体の投薬計画 Pending JP2023500480A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025131369A JP2025170788A (ja) 2019-11-01 2025-08-06 癌の治療のための抗cd27抗体の投薬計画

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962929538P 2019-11-01 2019-11-01
US62/929,538 2019-11-01
PCT/US2020/057817 WO2021087016A1 (en) 2019-11-01 2020-10-29 Dosing regimen of anti-cd27 antibodies for treatment of cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025131369A Division JP2025170788A (ja) 2019-11-01 2025-08-06 癌の治療のための抗cd27抗体の投薬計画

Publications (3)

Publication Number Publication Date
JP2023500480A JP2023500480A (ja) 2023-01-06
JP2023500480A5 true JP2023500480A5 (https=) 2023-11-08
JPWO2021087016A5 JPWO2021087016A5 (https=) 2023-11-08

Family

ID=75716307

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022525094A Pending JP2023500480A (ja) 2019-11-01 2020-10-29 癌の治療のための抗cd27抗体の投薬計画
JP2025131369A Pending JP2025170788A (ja) 2019-11-01 2025-08-06 癌の治療のための抗cd27抗体の投薬計画

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025131369A Pending JP2025170788A (ja) 2019-11-01 2025-08-06 癌の治療のための抗cd27抗体の投薬計画

Country Status (10)

Country Link
US (1) US20230192876A1 (https=)
EP (1) EP4051712A4 (https=)
JP (2) JP2023500480A (https=)
KR (1) KR20220092569A (https=)
CN (1) CN114761432A (https=)
AU (1) AU2020372912A1 (https=)
BR (1) BR112022008233A2 (https=)
CA (1) CA3159366A1 (https=)
MX (1) MX2022005245A (https=)
WO (1) WO2021087016A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12162940B2 (en) 2021-05-05 2024-12-10 Immatics Biotechnologies Gmbh BMA031 antigen binding polypeptides
WO2025188553A1 (en) * 2024-03-05 2025-09-12 Merck Sharp & Dohme Llc Methods and compositions for treatment of cancer with anti-cd27 antibodies

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011275749C1 (en) * 2010-07-09 2015-09-17 Aduro Biotech Holdings, Europe B.V. Agonistic antibody to CD27
US10392442B2 (en) * 2015-12-17 2019-08-27 Bristol-Myers Squibb Company Use of anti-PD-1 antibody in combination with anti-CD27 antibody in cancer treatment
JOP20190055A1 (ar) * 2016-09-26 2019-03-24 Merck Sharp & Dohme أجسام مضادة ضد cd27

Similar Documents

Publication Publication Date Title
BR112023005462A2 (https=)
BR112023012656A2 (https=)
BR112021014123A2 (https=)
BR112023009656A2 (https=)
BR112022009896A2 (https=)
BR112021017747A2 (https=)
BR112022024743A2 (https=)
BR112022026905A2 (https=)
BR112023011738A2 (https=)
BR112023004146A2 (https=)
BR112023006729A2 (https=)
BR102021018859A2 (https=)
BR102021015500A2 (https=)
BR102021007058A2 (https=)
BR102020022030A2 (https=)
BR112023016292A2 (https=)
BR112023011539A2 (https=)
BR112023011610A2 (https=)
BR112023008976A2 (https=)
BR102021020147A2 (https=)
BR102021018926A2 (https=)
BR102021018167A2 (https=)
BR102021017576A2 (https=)
BR102021016837A2 (https=)
BR102021016551A2 (https=)